Current Report Filing (8-k)
June 04 2019 - 06:41AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 4, 2019
IMMUNIC, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-36201
|
56-2358443
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
Am Klopferspitz 19
82152 Martinsried
Germany
|
|
|
(Address of principal executive offices)
|
|
Registrant’s telephone number, including
area code: 49 89 250079460
Vital Therapies, Inc.
15222-B Avenue of Science
San Diego, CA 92128
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value
|
IMUX
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging
growth company
ý
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange
Act. Yes
ý
No
¨
Item 7.01. Regulation FD Disclosure.
On June 4, 2019, Immunic, Inc. (the “Company”) issued
a press release with newly available preclinical data regarding IMU-935, one of the Company’s development programs. A copy
of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. A poster presentation of the preclinical
data is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form
8-K and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section, nor is it to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference
in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
Dated: June 4, 2019
|
Immunic, Inc.
|
|
|
|
|
By:
|
/s/ Daniel Vitt
|
|
|
Daniel Vitt
|
|
|
Chief Executive Officer
|
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Mar 2023 to Mar 2024